Do analysts prefer INMB or KROS?

Keros Therapeutics has a consensus price target of $20.50, suggesting a potential upside of 91.77%. Given Keros Therapeutics' higher possible upside, analysts plainly believe Keros Therapeutics is more favorable than INmune Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INmune Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Keros Therapeutics 2 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.22

Does the media prefer INMB or KROS?

In the previous week, Keros Therapeutics had 9 more articles in the media than INmune Bio. MarketBeat recorded 18 mentions for Keros Therapeutics and 9 mentions for INmune Bio. INmune Bio's average media sentiment score of 0.54 beat Keros Therapeutics' score of -0.11 indicating that INmune Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment INmune Bio 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Keros Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend GLSI or INMB?

Greenwich LifeSciences presently has a consensus target price of $57.00, indicating a potential upside of 267.74%. Given Greenwich LifeSciences' higher probable upside, analysts clearly believe Greenwich LifeSciences is more favorable than INmune Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Greenwich LifeSciences 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 INmune Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Is GLSI or INMB more profitable?

INmune Bio's return on equity of -82.87% beat Greenwich LifeSciences' return on equity. Company Net Margins Return on Equity Return on Assets Greenwich LifeSciences N/A -941.15% -368.53% INmune Bio N/A -82.87% -62.23%

Does the media refer more to GLSI or INMB?

In the previous week, INmune Bio had 6 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 9 mentions for INmune Bio and 3 mentions for Greenwich LifeSciences. INmune Bio's average media sentiment score of 0.54 beat Greenwich LifeSciences' score of 0.00 indicating that INmune Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Greenwich LifeSciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral INmune Bio 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate INMB or WHWK?

Whitehawk Therapeutics has a consensus price target of $8.20, suggesting a potential upside of 80.22%. Given Whitehawk Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Whitehawk Therapeutics is more favorable than INmune Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INmune Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Whitehawk Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63

Is INMB or WHWK more profitable?

Whitehawk Therapeutics' return on equity of -58.46% beat INmune Bio's return on equity. Company Net Margins Return on Equity Return on Assets INmune Bio N/A -82.87% -62.23% Whitehawk Therapeutics N/A -58.46% -53.81%

Does the media prefer INMB or WHWK?

In the previous week, INmune Bio had 2 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 9 mentions for INmune Bio and 7 mentions for Whitehawk Therapeutics. Whitehawk Therapeutics' average media sentiment score of 0.63 beat INmune Bio's score of 0.54 indicating that Whitehawk Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment INmune Bio 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Whitehawk Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend INMB or PYXS?

Pyxis Oncology has a consensus price target of $7.50, indicating a potential upside of 95.82%. Given Pyxis Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Pyxis Oncology is more favorable than INmune Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INmune Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Pyxis Oncology 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70

Is INMB or PYXS more profitable?

INmune Bio's return on equity of -82.87% beat Pyxis Oncology's return on equity. Company Net Margins Return on Equity Return on Assets INmune Bio N/A -82.87% -62.23% Pyxis Oncology N/A -135.60% -85.00%

Does the media refer more to INMB or PYXS?

In the previous week, INmune Bio had 5 more articles in the media than Pyxis Oncology. MarketBeat recorded 9 mentions for INmune Bio and 4 mentions for Pyxis Oncology. Pyxis Oncology's average media sentiment score of 0.63 beat INmune Bio's score of 0.54 indicating that Pyxis Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment INmune Bio 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pyxis Oncology 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate INMB or RNA?

Avidity Biosciences has a consensus price target of $63.85, suggesting a potential upside of 421.62%. Given Avidity Biosciences' higher probable upside, analysts plainly believe Avidity Biosciences is more favorable than INmune Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INmune Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Avidity Biosciences 1 Sell rating(s) 11 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.29

Is INMB or RNA more profitable?

Avidity Biosciences' return on equity of 0.00% beat INmune Bio's return on equity. Company Net Margins Return on Equity Return on Assets INmune Bio N/A -82.87% -62.23% Avidity Biosciences N/A N/A N/A

Does the media refer more to INMB or RNA?

In the previous week, Avidity Biosciences had 6 more articles in the media than INmune Bio. MarketBeat recorded 15 mentions for Avidity Biosciences and 9 mentions for INmune Bio. Avidity Biosciences' average media sentiment score of 0.90 beat INmune Bio's score of 0.54 indicating that Avidity Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment INmune Bio 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avidity Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

INmune Bio (INMB) Competitors

$2.12 +0.03 (+1.44%)

As of 04:00 PM Eastern

Compare

INMB vs. KROS, GLSI, WHWK, PYXS, and RNA

Should you buy INmune Bio stock or one of its competitors? INmune Bio's main competitors and comparable companies include Keros Therapeutics (KROS), Greenwich LifeSciences (GLSI), Whitehawk Therapeutics (WHWK), Pyxis Oncology (PYXS), and Avidity Biosciences (RNA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does INmune Bio compare to Keros Therapeutics?

INmune Bio (NASDAQ:INMB) and Keros Therapeutics (NASDAQ:KROS) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

12.7% of INmune Bio shares are owned by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are owned by institutional investors. 21.4% of INmune Bio shares are owned by company insiders. Comparatively, 12.6% of Keros Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

INmune Bio has a net margin of 0.00% compared to Keros Therapeutics' net margin of -256.60%. Keros Therapeutics' return on equity of -21.40% beat INmune Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INmune Bio	N/A	-82.87%	-62.23%
Keros Therapeutics	-256.60%	-21.40%	-19.79%

INmune Bio has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market. Comparatively, Keros Therapeutics has a beta of 0.99, suggesting that its share price is 1% less volatile than the broader market.

Keros Therapeutics has a consensus price target of $20.50, suggesting a potential upside of 91.77%. Given Keros Therapeutics' higher possible upside, analysts plainly believe Keros Therapeutics is more favorable than INmune Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Keros Therapeutics	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22

Keros Therapeutics has higher revenue and earnings than INmune Bio. INmune Bio is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INmune Bio	$50K	1,126.99	-$45.93M	-$0.67	N/A
Keros Therapeutics	$244.06M	0.87	$87.01M	-$3.70	N/A

In the previous week, Keros Therapeutics had 9 more articles in the media than INmune Bio. MarketBeat recorded 18 mentions for Keros Therapeutics and 9 mentions for INmune Bio. INmune Bio's average media sentiment score of 0.54 beat Keros Therapeutics' score of -0.11 indicating that INmune Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
INmune Bio	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Keros Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Keros Therapeutics beats INmune Bio on 9 of the 16 factors compared between the two stocks.

How does INmune Bio compare to Greenwich LifeSciences?

Greenwich LifeSciences (NASDAQ:GLSI) and INmune Bio (NASDAQ:INMB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, dividends, earnings, institutional ownership and analyst recommendations.

4.2% of Greenwich LifeSciences shares are owned by institutional investors. Comparatively, 12.7% of INmune Bio shares are owned by institutional investors. 51.5% of Greenwich LifeSciences shares are owned by company insiders. Comparatively, 21.4% of INmune Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Greenwich LifeSciences has a beta of 1.46, indicating that its stock price is 46% more volatile than the broader market. Comparatively, INmune Bio has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

In the previous week, INmune Bio had 6 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 9 mentions for INmune Bio and 3 mentions for Greenwich LifeSciences. INmune Bio's average media sentiment score of 0.54 beat Greenwich LifeSciences' score of 0.00 indicating that INmune Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Greenwich LifeSciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
INmune Bio	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Greenwich LifeSciences has higher earnings, but lower revenue than INmune Bio. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Greenwich LifeSciences	N/A	N/A	-$19.36M	-$1.57	N/A
INmune Bio	$50K	1,126.99	-$45.93M	-$0.67	N/A

INmune Bio's return on equity of -82.87% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Greenwich LifeSciences	N/A	-941.15%	-368.53%
INmune Bio	N/A	-82.87%	-62.23%

Greenwich LifeSciences presently has a consensus target price of $57.00, indicating a potential upside of 267.74%. Given Greenwich LifeSciences' higher probable upside, analysts clearly believe Greenwich LifeSciences is more favorable than INmune Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

INmune Bio beats Greenwich LifeSciences on 9 of the 14 factors compared between the two stocks.

How does INmune Bio compare to Whitehawk Therapeutics?

INmune Bio (NASDAQ:INMB) and Whitehawk Therapeutics (NASDAQ:WHWK) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Whitehawk Therapeutics has a consensus price target of $8.20, suggesting a potential upside of 80.22%. Given Whitehawk Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Whitehawk Therapeutics is more favorable than INmune Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

INmune Bio has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market. Comparatively, Whitehawk Therapeutics has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market.

Whitehawk Therapeutics has higher revenue and earnings than INmune Bio. Whitehawk Therapeutics is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INmune Bio	$50K	1,126.99	-$45.93M	-$0.67	N/A
Whitehawk Therapeutics	$7.14M	31.51	-$20.60M	-$1.12	N/A

Whitehawk Therapeutics' return on equity of -58.46% beat INmune Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INmune Bio	N/A	-82.87%	-62.23%
Whitehawk Therapeutics	N/A	-58.46%	-53.81%

In the previous week, INmune Bio had 2 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 9 mentions for INmune Bio and 7 mentions for Whitehawk Therapeutics. Whitehawk Therapeutics' average media sentiment score of 0.63 beat INmune Bio's score of 0.54 indicating that Whitehawk Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
INmune Bio	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Whitehawk Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

12.7% of INmune Bio shares are held by institutional investors. Comparatively, 52.1% of Whitehawk Therapeutics shares are held by institutional investors. 21.4% of INmune Bio shares are held by insiders. Comparatively, 49.9% of Whitehawk Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Whitehawk Therapeutics beats INmune Bio on 10 of the 15 factors compared between the two stocks.

How does INmune Bio compare to Pyxis Oncology?

INmune Bio (NASDAQ:INMB) and Pyxis Oncology (NASDAQ:PYXS) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.

In the previous week, INmune Bio had 5 more articles in the media than Pyxis Oncology. MarketBeat recorded 9 mentions for INmune Bio and 4 mentions for Pyxis Oncology. Pyxis Oncology's average media sentiment score of 0.63 beat INmune Bio's score of 0.54 indicating that Pyxis Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
INmune Bio	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pyxis Oncology	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

INmune Bio has higher earnings, but lower revenue than Pyxis Oncology. INmune Bio is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INmune Bio	$50K	1,126.99	-$45.93M	-$0.67	N/A
Pyxis Oncology	$13.86M	17.51	-$79.62M	-$1.31	N/A

INmune Bio has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market. Comparatively, Pyxis Oncology has a beta of 1.31, suggesting that its share price is 31% more volatile than the broader market.

12.7% of INmune Bio shares are owned by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are owned by institutional investors. 21.4% of INmune Bio shares are owned by company insiders. Comparatively, 5.7% of Pyxis Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

INmune Bio's return on equity of -82.87% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INmune Bio	N/A	-82.87%	-62.23%
Pyxis Oncology	N/A	-135.60%	-85.00%

Pyxis Oncology has a consensus price target of $7.50, indicating a potential upside of 95.82%. Given Pyxis Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Pyxis Oncology is more favorable than INmune Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Summary

INmune Bio beats Pyxis Oncology on 8 of the 15 factors compared between the two stocks.

How does INmune Bio compare to Avidity Biosciences?

INmune Bio (NASDAQ:INMB) and Avidity Biosciences (NASDAQ:RNA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

12.7% of INmune Bio shares are held by institutional investors. 21.4% of INmune Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Avidity Biosciences' return on equity of 0.00% beat INmune Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INmune Bio	N/A	-82.87%	-62.23%
Avidity Biosciences	N/A	N/A	N/A

In the previous week, Avidity Biosciences had 6 more articles in the media than INmune Bio. MarketBeat recorded 15 mentions for Avidity Biosciences and 9 mentions for INmune Bio. Avidity Biosciences' average media sentiment score of 0.90 beat INmune Bio's score of 0.54 indicating that Avidity Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
INmune Bio	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Avidity Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Avidity Biosciences has lower revenue, but higher earnings than INmune Bio. Avidity Biosciences is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INmune Bio	$50K	1,126.99	-$45.93M	-$0.67	N/A
Avidity Biosciences	N/A	N/A	N/A	-$0.97	N/A

Avidity Biosciences has a consensus price target of $63.85, suggesting a potential upside of 421.62%. Given Avidity Biosciences' higher probable upside, analysts plainly believe Avidity Biosciences is more favorable than INmune Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Avidity Biosciences	1 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.29

Summary

Avidity Biosciences beats INmune Bio on 6 of the 11 factors compared between the two stocks.

Get INmune Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INMB vs. The Competition

Export

Metric	INmune Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$55.43M	$3.72B	$7.06B	$12.95B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	N/A	9.13	269.75	24.74
Price / Sales	1,126.99	1,274.20	652.34	108.60
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	2.41	17.66	11.27	6.42
Net Income	-$45.93M	-$13.25M	$3.45B	$347.12M
7 Day Performance	14.59%	5.36%	3.56%	2.48%
1 Month Performance	9.28%	-1.74%	-0.58%	-1.04%
1 Year Performance	-17.19%	61.36%	77.52%	23.22%

INmune Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INMB INmune Bio	1.0823 of 5 stars	$2.12 +1.4%	N/A	-18.6%	$55.43M	$50K	N/A	10	Earnings Report Analyst Upgrade
KROS Keros Therapeutics	3.0701 of 5 stars	$10.24 +1.3%	$20.50 +100.2%	-18.8%	$201.86M	$244.06M	N/A	100	Earnings Report Analyst Upgrade Gap Down
GLSI Greenwich LifeSciences	2.043 of 5 stars	$13.79 +1.8%	$57.00 +313.3%	+17.9%	$200.91M	N/A	N/A	3	Upcoming Earnings Gap Up
WHWK Whitehawk Therapeutics	2.4637 of 5 stars	$4.05 +2.1%	$8.20 +102.7%	+172.0%	$198.80M	N/A	N/A	21	Earnings Report Analyst Upgrade
PYXS Pyxis Oncology	3.1566 of 5 stars	$3.11 +2.4%	$7.50 +140.9%	+251.9%	$196.70M	$13.86M	N/A	60	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INMB) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

INmune Bio (INMB) Competitors

INMB vs. KROS, GLSI, WHWK, PYXS, and RNA

How does INmune Bio compare to Keros Therapeutics?

Summary

How does INmune Bio compare to Greenwich LifeSciences?

Summary

How does INmune Bio compare to Whitehawk Therapeutics?

Summary

How does INmune Bio compare to Pyxis Oncology?

Summary

How does INmune Bio compare to Avidity Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INMB vs. The Competition

INmune Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

INmune Bio (INMB) Competitors

INMB vs. KROS, GLSI, WHWK, PYXS, and RNA

How does INmune Bio compare to Keros Therapeutics?

Do institutionals and insiders hold more shares of INMB or KROS?

Is INMB or KROS more profitable?

Which has more risk & volatility, INMB or KROS?

Do analysts prefer INMB or KROS?

Which has better valuation & earnings, INMB or KROS?

Does the media prefer INMB or KROS?

Summary

How does INmune Bio compare to Greenwich LifeSciences?

Do insiders & institutionals have more ownership in GLSI or INMB?

Which has more risk and volatility, GLSI or INMB?

Does the media refer more to GLSI or INMB?

Which has higher earnings & valuation, GLSI or INMB?

Is GLSI or INMB more profitable?

Do analysts recommend GLSI or INMB?

Summary

How does INmune Bio compare to Whitehawk Therapeutics?

Do analysts rate INMB or WHWK?

Which has more volatility & risk, INMB or WHWK?

Which has stronger valuation and earnings, INMB or WHWK?

Is INMB or WHWK more profitable?

Does the media prefer INMB or WHWK?

Do insiders and institutionals hold more shares of INMB or WHWK?

Summary

How does INmune Bio compare to Pyxis Oncology?

Does the media refer more to INMB or PYXS?

Which has stronger earnings and valuation, INMB or PYXS?

Which has more risk & volatility, INMB or PYXS?

Do institutionals & insiders have more ownership in INMB or PYXS?

Is INMB or PYXS more profitable?

Do analysts recommend INMB or PYXS?

Summary

How does INmune Bio compare to Avidity Biosciences?

Do institutionals and insiders hold more shares of INMB or RNA?

Is INMB or RNA more profitable?

Does the media refer more to INMB or RNA?

Which has higher valuation & earnings, INMB or RNA?

Do analysts rate INMB or RNA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INMB vs. The Competition

INmune Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools